生物
CDKN2A
癌症研究
外显子组测序
表观遗传学
突变
组蛋白
细胞周期
BAP1型
体细胞
外显子组
遗传学
基因
癌变
作者
Yibo Gao,Zhao-Li Chen,Jia-Gen Li,Xue-Da Hu,Xue-Jiao Shi,Zeng-Miao Sun,Fan Zhang,Zi-Ran Zhao,Zi-Tong Li,Zi-Yuan Liu,Yu-Da Zhao,Jian Sun,Cheng-Cheng Zhou,Ran Yao,Su-Ya Wang,Pan Wang,Nan Sun,Bai-Hua Zhang,Jing-Si Dong,Yue Yu
出处
期刊:Nature Genetics
[Nature Portfolio]
日期:2014-08-24
卷期号:46 (10): 1097-1102
被引量:647
摘要
Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers. We performed exome sequencing on 113 tumor-normal pairs, yielding a mean of 82 non-silent mutations per tumor, and 8 cell lines. The mutational profile of ESCC closely resembles those of squamous cell carcinomas of other tissues but differs from that of esophageal adenocarcinoma. Genes involved in cell cycle and apoptosis regulation were mutated in 99% of cases by somatic alterations of TP53 (93%), CCND1 (33%), CDKN2A (20%), NFE2L2 (10%) and RB1 (9%). Histone modifier genes were frequently mutated, including KMT2D (also called MLL2; 19%), KMT2C (MLL3; 6%), KDM6A (7%), EP300 (10%) and CREBBP (6%). EP300 mutations were associated with poor survival. The Hippo and Notch pathways were dysregulated by mutations in FAT1, FAT2, FAT3 or FAT4 (27%) or AJUBA (JUB; 7%) and NOTCH1, NOTCH2 or NOTCH3 (22%) or FBXW7 (5%), respectively. These results define the mutational landscape of ESCC and highlight mutations in epigenetic modulators with prognostic and potentially therapeutic implications.
科研通智能强力驱动
Strongly Powered by AbleSci AI